Arjan van de Loosdrecht, Eva-Maria Wagner Drouet, Uwe Platzbecker, Tobias A.W. Holderried, Janine Van Elssen, Aristoteles Giagounidis, Sören Lehmann, Jacqueline Cloos, Hester Van Zeeburg, Jeroen Rovers, Alex Karlsson-Parra, Tariq Mughal, Bjorn Gjertsen. "Post-remission immunotherapy with vididencel for a measurable residual disease defined high-risk sub-group of adult patients with Acute Myeloid Leukemia in first complete hematological remission: Updated results of the european advance II study demonstrate robust safety, relapse-free and overall survival benefit.." Blood, 2025. doi:10.1182/blood-2025-1647